ORIGINAL ARTICLE
Comprehensive analysis in mucin-producing urothelial-type adenocarcinoma of the prostate: case study with literature review
1
Department of Pathology, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan
2
Department of Internal Medicine, Fu-Jen Catholic University Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan
3
Associate Dean of College of Science and Engineering, Director of Graduate Institute of Applied Science and Engineering, Department and Institute of Life-Science, Fu-Jen Catholic University, New Taipei, Taiwan
Submission date: 2019-07-02
Final revision date: 2019-09-09
Acceptance date: 2019-10-06
Publication date: 2020-10-25
Pol J Pathol 2020;71(3):244-253
KEYWORDS
TOPICS
ABSTRACT
It is critical to distinguish the rare neoplasm of mucin-producing urothelial-type adenocarcinoma of the prostate (MPUAP) from either prostate origin or metastatic adenocarcinoma. This is mainly because they have different tumor staging, clinical behavior and treatment plans. In the current study, we try to fulfill the lack of knowledge in this field.
There were totally 24 MPUAP cases including previous reported 23 cases and adding one new MPUAP case in the current study. We performed IHC and 78 genes panel analysis in two cases of ours.
Most of the cases had urinary obstruction symptoms and normal PSA level. Pathological features showed dissection of the stroma by mucin pools and glands lined by pseudostratified columnar mucinous epithelium with varying degrees of cytological atypia. The IHC results showed positive for CK20, CEA, CDX-2, β-catenin, p53, MUC2 and MUC5AC, negative for PSA, AMACR, GATA3, MUC6, AR and NKX3.1 and variable expression for HMWCK and CK7. Genetic analysis revealed concurrent mutations of FAT1 (c.10001 T>C) and HNF1A in both cases.
The similar morphology features of MPUAP and colorectal adenocarcinoma were seen. Membranous staining pattern of β-catenin and genetic mutation of FAT1 and HNF1A are two distinct features in MPUAP.
There were totally 24 MPUAP cases including previous reported 23 cases and adding one new MPUAP case in the current study. We performed IHC and 78 genes panel analysis in two cases of ours.
Most of the cases had urinary obstruction symptoms and normal PSA level. Pathological features showed dissection of the stroma by mucin pools and glands lined by pseudostratified columnar mucinous epithelium with varying degrees of cytological atypia. The IHC results showed positive for CK20, CEA, CDX-2, β-catenin, p53, MUC2 and MUC5AC, negative for PSA, AMACR, GATA3, MUC6, AR and NKX3.1 and variable expression for HMWCK and CK7. Genetic analysis revealed concurrent mutations of FAT1 (c.10001 T>C) and HNF1A in both cases.
The similar morphology features of MPUAP and colorectal adenocarcinoma were seen. Membranous staining pattern of β-catenin and genetic mutation of FAT1 and HNF1A are two distinct features in MPUAP.
REFERENCES (39)
1.
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 cancer incidence and mortality worldwide: IARC cancerbase No. 11. Lyon, France: International Agency for Research on Cancer, 2013.
2.
Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology 2012; 60: 59-74.
3.
Mazzucchelli R, Lopez-Beltran A, Cheng L, et al. Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int 2008; 102: 1369-1374.
4.
Tran KP, Epstein JI. Mucinous adenocarcinoma of urinary bladder type arising from the prostatic urethra. Distinction from mucinous adenocarcinoma of the prostate. Am J Surg Pathol 1996; 20: 1346-1350.
5.
Ortiz-Rey JA, Dos Santos JE, Rodríguez-Castilla M, et al. Mucinous urothelial-type adenocarcinoma of the prostate. Scand J Urol Nephrol 2004; 38: 256-257.
6.
Curtis MW, Evans AJ, Srigley JR. Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity. Mod Pathol 2005; 18: 585-590.
7.
Adley BP, Maxwell K, Dalton DP, Yang XJ. Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma. Int Braz J Urol 2006; 32: 681-687.
8.
Niu H, Sun G, Chang J, et al. Mucin-producing urothelial-type adenocarcinoma of the prostate (a case report and review of the literature). Chin J Clin Oncol 2006; 3: 370-372.
9.
Osunkoya AO, Epstein JI. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol 2007; 31: 1323-1329.
10.
Chen YL, Chian JH, Hsiao PJ. Mucin-producing urothelial-type adenocarcinoma of the prostate as a mimicker of colonic adenocarcinoma: a case report and review of the literature. Int J Surg Pathol 2012; 20: 191-195.
11.
Sebesta EM, Mirheydar HS, Parsons JK, et al. Primary mucin-producing urothelial-type adenocarcinoma of the prostatic urethra diagnosed on TURP: a case report and review of literature. BMC Urol 2014; 14: 39.
12.
Kawasaki T, Saito T, Uchida K, et al. A case of mucin-producing urothelial-type adenocarcinoma of the prostate showing immunoreactivity for NKX3.1, a specific marker of prostatic tissue. Pathol Int 2017; 67: 483-484.
13.
Epstein JI. Prostatic ductal adenocarcinoma: a mini review. Med Princ Pract 2010; 19: 82-85.
14.
Seipel AH, Samaratunga H, Delahunt B, et al. Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Archiv 2014; 465: 559-565.
15.
Herawi M, Epstein JI. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol 2007; 31: 889-894.
16.
Wang HL, Lu DW, Yerian LM, et al. Immunohistochemical distinction between primary adenocarcinoma of the urinary bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol 2001; 25: 1380-1387.
17.
Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-689.
18.
Barbieri CE, Tomlins SA. The prostate cancer genome: perspectives and potential. Urol Oncol 2014; 32: 53 e15-e22.
19.
Sun X, Huang J, Homma T, et al. Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res 2009; 29: 1739-1743.
20.
Beltran H, Yelensky R, Frampton GM, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013; 63: 920-926.
21.
Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-243.
22.
Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
23.
Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010; 16: 793-798.
24.
Wang XS, Shankar S, Dhanasekaran SM, et al. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov 2011; 1: 35-43.
25.
Sirintrapun SJ, Ward M, Woo J, Cimic A. High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations. Hum Pathol 2014; 45: 327-330.
26.
Alexander RE, Lopez-Beltran A, Montironi R, et al. KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. Histopathology 2012; 61: 1036-1042.
27.
Morris LG, Kaufman AM, Gong Y, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet 2013; 45: 253-261.
28.
Hou R, Liu L, Anees S, et al. The Fat1 cadherin integrates vascular smooth muscle cell growth and migration signals. J Cell Biol 2006; 173: 417-429.
29.
Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480.
30.
The Sanger Institute Catalogue of Somatic Mutation in Cancer (COSMIC) web site. Available at https://cancer.sanger.ac.uk/co... (Accessed on June 8 2018).
31.
The Sanger Institute Catalogue of Somatic Mutation in Cancer (COSMIC) web site. Available at https://cancer.sanger.ac.uk/co... (Accessed on June 8 2018).
32.
Maestro MA, Cardalda C, Boj SF, et al. Distinct roles of HNF1beta, HNF1alpha, and HNF4alpha in regulating pancreas development, beta-cell function and growth. Endocr Dev 2007; 12: 33-45.
33.
Real Hernandez LM, Fan J, Johnson MH, Gonzalez de Mejia E. Berry phenolic compounds increase expression of hepatocyte nuclear factor-1alpha (HNF-1alpha) in Caco-2 and normal colon cells due to high affinities with transcription and dimerization domains of HNF-1alpha. PloS One 2015; 10: e0138768.
34.
Armendariz AD, Krauss RM. Hepatic nuclear factor 1-alpha: inflammation, genetics, and atherosclerosis. Curr Opin Lipidol 2009; 20: 106-111.
35.
Shih DQ, Bussen M, Sehayek E, et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001; 27: 375-382.
36.
Luo Z, Li Y, Wang H, et al. Hepatocyte nuclear factor 1A (HNF1A) as a possible tumor suppressor in pancreatic cancer. PloS One 2015; 10: e0121082.
37.
Lussier CR, Brial F, Roy SA, et al. Loss of hepatocyte-nuclear-factor-1alpha impacts on adult mouse intestinal epithelial cell growth and cell lineages differentiation. PloS One 2010; 5: e12378.
38.
The Sanger Institute Catalogue of Somatic Mutation in Cancer (COSMIC) web site. Available at https://cancer.sanger.ac.uk/co... (Accessed on June 8 2018).
39.
The Sanger Institute Catalogue of Somatic Mutation in Cancer (COSMIC) web site. Available at https://cancer.sanger.ac.uk/co... (Accessed on June 8 2018).
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
